Scripps Research Develops Broad-Spectrum Fentanyl Vaccine That Blocks Multiple Synthetic Opioids

Researchers at Scripps Research published findings in the Journal of Medicinal Chemistry describing a new vaccine architecture that provides broad-spectrum protection against multiple fentanyl analogs, including some of the most potent synthetic opioids on the black market.

The research, led by senior scientist Kim Janda, uses a reconfigured molecular architecture rather than fentanyl itself to train the immune system. By creating a non-canonical molecule that retains key molecular cues shared across the fentanyl drug family, the team successfully elicited a broad-spectrum antibody response in animal models.

The vaccine demonstrated high affinity for potent analogs including carfentanil, China White, acetylfentanyl, and furanylfentanyl, while notably sparing therapeutic opioids like morphine and oxycodone. This selectivity is important because it means the vaccine would not interfere with legitimate pain management.

In vaccinated mice, fentanyl penetration into the brain was reduced by approximately 70 percent compared to unvaccinated controls. Vaccinated animals also maintained stable respiratory rates despite exposure to lethal doses of fentanyl.

"The goal is to create a vaccine that works against the entire class of synthetic opioids, not just one specific compound," Janda said. "Drug manufacturers on the black market constantly modify their formulas to evade detection. A broad-spectrum vaccine can stay ahead of those changes."

A separate fentanyl vaccine candidate, developed by Dr. Colin Haile at the University of Houston and licensed by the startup ARMR Sciences, entered Phase 1 human clinical trials in the Netherlands in January 2026. That vaccine uses a synthetic fentanyl fragment to trigger antibody production and is being tested in 40 participants.

Fentanyl and its analogs are responsible for the majority of the more than 70,000 opioid overdose deaths that occur in the United States each year. A vaccine that could prevent overdoses would represent a significant advance in addiction medicine.

Researchers caution that human trials are still years away for the Scripps vaccine, and that even a successful vaccine would need to be combined with other treatment approaches including medication-assisted treatment and behavioral therapy.